Generic Liability: Supreme Court Appears Divided On Whether ANDA Sponsors Must Seek Label Change When New Risks Emerge
This article was originally published in The Pink Sheet Daily
Executive Summary
In oral arguments in Pliva v. Mensing, justices suggest generic companies have an obligation to ask FDA to revise labeling; Chief Justice John Roberts Jr. says that could lead to boilerplate letters to FDA.
You may also be interested in...
Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change
In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.
Generic Firms Get Supreme Shield From Product Liability, But Court Hints At Reg Change
In Pliva v. Mensing, the high court said it was impossible for generic manufacturers to comply with both state tort laws and FDA regulations requiring them to have the same labels as those for brand name counterparts.
Generic Industry Faces Uphill Battle In Preemption Case Before Supreme Court
Generic companies appear to be the underdogs as they head to the Supreme Court to argue they should not be held liable for inadequate label warnings.